Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder

Cheema, Nadir; Frangou, Sophia; McCrone, Paul

doi:10.1177/2045125312464105

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In all, 16 studies use a healthcare perspective [ 7 , 8 , 50 – 52 , 63 , 65 – 68 , 70 – 73 , 75 , 76 ], while nine adopt a societal perspective [ 6 , 9 , 53 , 55 , 56 , 59 , 60 , 64 , 77 ]. Only two studies use the payer perspective [ 57 , 62 ], and the rest present results for both the healthcare and societal perspectives [ 54 , 58 , 61 , 69 , 74 ].…”

Section: Resultsmentioning

confidence: 99%

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

Jörg

et al. 2022

PharmacoEconomics

View full text Add to dashboard Cite

The most appropriate next step in depression treatment after the initial treatment fails is unclear. This study explores the suitability of the Markov decision process for optimizing sequential treatment decisions for depression. We conducted a formal comparison of a Markov decision process approach and mainstream state-transition models as used in health economic decision analysis to clarify differences in the model structure. We performed two reviews: the first to identify existing applications of the Markov decision process in the field of healthcare and the second to identify existing health economic models for depression. We then illustrated the application of a Markov decision process by reformulating an existing health economic model. This provided input for discussing the suitability of a Markov decision process for solving sequential treatment decisions in depression. The Markov decision process and state-transition models differed in terms of flexibility in modeling actions and rewards. In all, 23 applications of a Markov decision process within the context of somatic disease were included, 16 of which concerned sequential treatment decisions. Most existing health economic models relating to depression have a state-transition structure. The example application replicated the health economic model and enabled additional capacity to make dynamic comparisons of more interventions over time than was possible with traditional state-transition models. Markov decision processes have been successfully applied to address sequential treatment-decision problems, although the results have been published mostly in economics journals that are not related to healthcare. One advantage of a Markov decision process compared with state-transition models is that it allows extended action space: the possibility of making dynamic comparisons of different treatments over time. Within the context of depression, although existing state-transition models are too basic to evaluate sequential treatment decisions, the assumptions of a Markov decision process could be satisfied. The Markov decision process could therefore serve as a powerful model for optimizing sequential treatment in depression. This would require a sufficiently elaborate state-transition model at the cohort or patient level.

show abstract

Section: Resultsmentioning

confidence: 99%

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

Jörg

et al. 2022

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder

Mohiuddin

2014

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Objectives The main objective of this study was to derive cost estimates of five major foodborne illnesses (campylobacteriosis, salmonellosis, enterohemorrhagic Escherichia coli (EHEC), yersiniosis and shigellosis) in Sweden. These estimates provide a necessary contribution to perform future cost-benefit analyses aimed at reducing the burden of foodborne disease. A secondary aim was to obtain estimates of the true number of cases that occur in the community, thus providing necessary ground for calculating costs. Methods The true number of cases for each foodborne illness was simulated by multiplying the reported number of cases by sequential multipliers, one for each potential source of information loss about a case. This assessment of the true number of cases was then used to estimate the number of cases of sequelae for each illness. An incidence-based analysis was then used to calculate direct medical and non-medical costs, as well as indirect costs. Data for estimating the true number of cases for each illness were primarily based on an expert panel, while the derivation of costs mainly utilized national registries, databases and published literature. Results The estimated number of cases was between 7-and 11-fold higher than the reported number of cases, indicating the importance of taking information loss into account when calculating costs. By far the most common pathogen of the five was campylobacter, with an estimated 101,719 (90% credibility interval [CI] 59,640-158,025) human cases occurring annually. For salmonella, 19,678 (90% CI 8394-40,456) cases were estimated to occur each year, while the other three pathogens were less common, with a yearly incidence of approximately 2500-5500 cases each. The total cost for the five pathogens (including sequelae) amounted to €142 million annually. Campylobacter was the most costly pathogen, representing 69% of the total costs. Salmonellosis and EHEC constituted 18 and 9% of these costs, respectively, while yersiniosis and shigellosis represented approximately 2% each. Costs for sequelae were significant and accounted for approximately 50% of the total costs. Conclusions Our simulations indicated that campylobacter infection was more common and more costly than salmonella, EHEC, yersinia and shigella combined. Estimated costs for all illnesses were highly influenced by (1) considering potential information losses about cases in the population (which increased costs 7-to 11-fold), and (2) taking account of postinfection sequelae (which doubled the costs). Key Points for Decision MakersThis study estimates the difference between registered and actual number of cases in the community for five major foodborne diseases. Potential post-infection sequelae are included in the analysis. These considerations are crucial in order to assess the actual societal burden of the five pathogens.The study also estimates total societal costs and costs per case for the five pathogens, results that can be utilized in future cost-benefit or cost-effectiveness studies.

show abstract

The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

2013

View full text Add to dashboard Cite

show abstract

Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder

Cited by 3 publications

References 11 publications

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

A Promising Approach to Optimizing Sequential Treatment Decisions for Depression: Markov Decision Process

A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder

The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review

Contact Info

Product

Resources

About